The True Promise of Quality by Design: Risks & Rewards
In this exclusive interview Jesús Zurdo, Head of Innovation, Biopharma Development, Lonza Biologics, speaks to Andrea Charles from Pharma IQ about improving the developability of biopharmaceuticals, the advantages of implementing early risk assessment and enhancing manufacture through Quality By Design (QbD). Zurdo also shares his views on the future and true promise of QbD.
Pharma IQ: What sort of current trends have you witnessed, with regards to improving the developability of bio...
To continue reading this story get free access